CU24325B1 - Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores - Google Patents

Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores

Info

Publication number
CU24325B1
CU24325B1 CUP2014000103A CU20140103A CU24325B1 CU 24325 B1 CU24325 B1 CU 24325B1 CU P2014000103 A CUP2014000103 A CU P2014000103A CU 20140103 A CU20140103 A CU 20140103A CU 24325 B1 CU24325 B1 CU 24325B1
Authority
CU
Cuba
Prior art keywords
modulators
disorders associated
treat diseases
calcium sensitive
sensitive receiver
Prior art date
Application number
CUP2014000103A
Other languages
English (en)
Other versions
CU20140103A7 (es
Inventor
Rajender Kumar Kamboj
Talha Hussain Khan
Sanjeev Anant Kulkarni
Rajeshkumar Maganlal Loriya
Vipul Dilip Pachpute
Venkata P Palle
Ankush Gangaram Sarde
Manojkumar Ramprasad Shukla
Navnath Bajirao Walke
Original Assignee
Lupin Atlantis Holdings Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Atlantis Holdings Sa filed Critical Lupin Atlantis Holdings Sa
Publication of CU20140103A7 publication Critical patent/CU20140103A7/es
Publication of CU24325B1 publication Critical patent/CU24325B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analyzing Non-Biological Materials By The Use Of Chemical Means (AREA)

Abstract

<p>La presente invención proporciona moduladores del receptor sensible al calcio (CaSR). En particular, los compuestos descritos en la presente son útiles para tratar, manejar y/o reducir la gravedad de enfermedades, trastornos, síndromes y/o afecciones asociados con la modulación de los receptores sensibles al calcio (CaSR).</p> <p>ESPACIO PARA FÓRMULA I</p>
CUP2014000103A 2012-02-24 2013-02-22 Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores CU24325B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN178KO2012 2012-02-24
IN1030KO2012 2012-09-07
PCT/IB2013/051445 WO2013124828A1 (en) 2012-02-24 2013-02-22 Substituted chroman compounds as calcium sensing receptor modulators

Publications (2)

Publication Number Publication Date
CU20140103A7 CU20140103A7 (es) 2015-01-29
CU24325B1 true CU24325B1 (es) 2018-03-13

Family

ID=54261188

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000103A CU24325B1 (es) 2012-02-24 2013-02-22 Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores

Country Status (44)

Country Link
US (3) US9163001B2 (es)
EP (1) EP2817299B1 (es)
JP (1) JP6114316B2 (es)
KR (1) KR102041154B1 (es)
CN (1) CN104350047B (es)
AP (1) AP2014007919A0 (es)
AR (1) AR090135A1 (es)
AU (1) AU2013223715B2 (es)
BR (1) BR112014021133B1 (es)
CA (1) CA2864332C (es)
CL (1) CL2014002218A1 (es)
CO (1) CO7160018A2 (es)
CR (1) CR20140424A (es)
CU (1) CU24325B1 (es)
CY (1) CY1122017T1 (es)
DK (1) DK2817299T3 (es)
DO (1) DOP2014000193A (es)
EA (1) EA026940B9 (es)
ES (1) ES2743492T3 (es)
GE (1) GEP20186911B (es)
GT (1) GT201400179A (es)
HK (1) HK1205117A1 (es)
HR (1) HRP20191606T1 (es)
HU (1) HUE046172T2 (es)
IL (1) IL234252A (es)
IN (1) IN2014MN01672A (es)
LT (1) LT2817299T (es)
MA (1) MA35937B1 (es)
MX (1) MX355670B (es)
MY (1) MY171374A (es)
NI (1) NI201400094A (es)
NZ (1) NZ628627A (es)
PE (1) PE20142281A1 (es)
PH (1) PH12014501891A1 (es)
PL (1) PL2817299T3 (es)
PT (1) PT2817299T (es)
RS (1) RS59172B1 (es)
SG (1) SG11201405117SA (es)
SI (1) SI2817299T1 (es)
TN (1) TN2014000352A1 (es)
TW (1) TWI617549B (es)
UA (1) UA112679C2 (es)
WO (1) WO2013124828A1 (es)
ZA (1) ZA201405990B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE046172T2 (hu) * 2012-02-24 2020-02-28 Lupin Ltd Szubsztituált krománvegyületek mint kalcium-szenzor receptor modulátorok
JP2015528462A (ja) * 2012-08-27 2015-09-28 ルピン・リミテッドＬｕｐｉｎ Ｌｉｍｉｔｅｄ カルシウム感知受容体モジュレーターとしてのアリールアルキルアミン化合物
TW201602062A (zh) 2013-08-12 2016-01-16 魯賓有限公司 取代聯苯基化合物作為鈣敏感受體調節劑
AU2014313835A1 (en) 2013-08-28 2016-03-03 Lupin Atlantis Holdings Sa Substituted naphthalene compounds as calcium sensing receptor modulators
WO2015162538A1 (en) 2014-04-21 2015-10-29 Lupin Limited Heterocyclic compounds as calcium sensing receptor modulators for the treatment of hyperparathyroidism, chronic renal failure and chronic kidney disease
WO2017037616A1 (en) 2015-08-31 2017-03-09 Lupin Limited Arylalkylamine compounds as calcium sensing receptor modulators
EP4061805A1 (en) 2019-11-19 2022-09-28 Lupin Limited Process for preparing chroman compounds
MX2022007939A (es) 2019-12-27 2022-07-27 Lupin Ltd Composiciones farmaceuticas de moduladores de casr y metodos y usos de las mismas.
CA3166512A1 (en) * 2020-01-17 2021-07-22 Lupin Limited Methods, processes and intermediates for preparing chroman compounds

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3063585D1 (en) * 1979-05-19 1983-07-07 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
US5387587A (en) * 1986-12-23 1995-02-07 Merck Patent Gesellschaft Mit Beschrankter Haftung Chroman derivatives
US6133277A (en) 1997-12-05 2000-10-17 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
FR2812875B1 (fr) 2000-08-08 2003-12-12 Centre Nat Rech Scient Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
WO2004069793A2 (en) 2003-01-28 2004-08-19 Bristol-Myers Squibb Company Novel 2-substituted cyclic amines as calcium sensing receptor modulators
WO2004106280A1 (ja) 2003-05-28 2004-12-09 Japan Tobacco Inc. ＣａＳＲアンタゴニスト
CN101175724B (zh) 2005-05-19 2011-12-07 安斯泰来制药有限公司 吡咯烷衍生物或其盐
TW200815388A (en) 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
MX2009003673A (es) 2006-10-04 2009-04-22 Pfizer Prod Inc Derivados de piridido[4,3-d]pirimidin-4(3h)-ona como antagonistas de los receptores de calcio.
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
CA2669635A1 (en) 2006-11-16 2008-05-22 Astellas Pharma Inc. Piperidine derivative or salt thereof
AU2008311974B2 (en) * 2007-10-15 2013-11-21 Amgen Inc. Calcium receptor modulating agents
KR20100108348A (ko) 2007-11-23 2010-10-06 레오 파마 에이/에스 질병 치료용의 신규한 사이클릭 탄화수소 화합물
KR101700152B1 (ko) 2008-10-03 2017-01-26 이에이 파마 가부시키가이샤 ＣａＳＲ 효능제
WO2010042642A1 (en) 2008-10-08 2010-04-15 Amgen Inc. Calcium receptor modulating agents
WO2010136037A1 (en) 2009-05-27 2010-12-02 Leo Pharma A/S Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
US20130261132A1 (en) 2010-11-26 2013-10-03 Leo Pharma A/S Calcium-sensing receptor-active compounds
US20130245084A1 (en) 2010-11-26 2013-09-19 Leo Pharma A/S Calcium-sensing receptor-active compounds
JP2014500882A (ja) 2010-11-26 2014-01-16 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
CA2828415A1 (en) 2011-03-10 2012-09-13 Lupin Limited Substituted morpholines as modulators for the calcium sensing receptor
JP6033835B2 (ja) 2011-03-18 2016-11-30 ルピン アトランティス ホールディングス エスエー カルシウム感知受容体モジュレーターとしてのベンゾ［ｂ］［１，４］オキサジン誘導体
HUE046172T2 (hu) * 2012-02-24 2020-02-28 Lupin Ltd Szubsztituált krománvegyületek mint kalcium-szenzor receptor modulátorok

Also Published As

Publication number Publication date
DK2817299T3 (da) 2019-09-16
MX355670B (es) 2018-04-25
EP2817299B1 (en) 2019-06-12
HUE046172T2 (hu) 2020-02-28
US20170209410A1 (en) 2017-07-27
DOP2014000193A (es) 2017-01-15
ZA201405990B (en) 2015-11-25
KR20140135731A (ko) 2014-11-26
HRP20191606T1 (hr) 2019-12-13
KR102041154B1 (ko) 2019-11-07
EA026940B1 (ru) 2017-06-30
CL2014002218A1 (es) 2015-03-06
AR090135A1 (es) 2014-10-22
EP2817299A1 (en) 2014-12-31
UA112679C2 (uk) 2016-10-10
BR112014021133A2 (pt) 2018-09-11
PL2817299T3 (pl) 2019-12-31
JP2015508097A (ja) 2015-03-16
AU2013223715A1 (en) 2014-08-28
US9163001B2 (en) 2015-10-20
MX2014010139A (es) 2015-09-04
BR112014021133B1 (pt) 2022-06-28
CA2864332A1 (en) 2013-08-29
US9598391B2 (en) 2017-03-21
SG11201405117SA (en) 2014-09-26
EA201491582A1 (ru) 2014-12-30
PT2817299T (pt) 2019-09-23
GT201400179A (es) 2016-03-01
JP6114316B2 (ja) 2017-04-12
CA2864332C (en) 2020-08-25
PH12014501891B1 (en) 2015-02-09
MY171374A (en) 2019-10-10
CN104350047B (zh) 2017-05-24
US20150368222A1 (en) 2015-12-24
RS59172B1 (sr) 2019-10-31
NI201400094A (es) 2015-03-27
CN104350047A (zh) 2015-02-11
US9987249B2 (en) 2018-06-05
GEP20186911B (en) 2018-10-25
HK1205117A1 (en) 2015-12-11
CR20140424A (es) 2015-01-13
EA026940B9 (ru) 2017-11-30
TW201336831A (zh) 2013-09-16
MA35937B1 (fr) 2014-12-01
NZ628627A (en) 2017-02-24
TN2014000352A1 (en) 2015-12-21
LT2817299T (lt) 2019-09-25
CO7160018A2 (es) 2015-01-15
PE20142281A1 (es) 2015-01-16
CU20140103A7 (es) 2015-01-29
TWI617549B (zh) 2018-03-11
AP2014007919A0 (en) 2014-09-30
IL234252A (en) 2017-02-28
SI2817299T1 (sl) 2019-10-30
WO2013124828A1 (en) 2013-08-29
CY1122017T1 (el) 2020-10-14
ES2743492T3 (es) 2020-02-19
IN2014MN01672A (es) 2015-05-29
PH12014501891A1 (en) 2015-02-09
US20150038546A1 (en) 2015-02-05
AU2013223715B2 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
CU24325B1 (es) Compuestos de cromano sustituidos como modulares del receptor sensible al calcio para tratar enfermedades o desórdenes asociados con estos moduladores
UY37610A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
GT201400275A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huèrfano rory
CR20150255A (es) Derivados triciclicos fusionados de tiofeno como inhibidores de jak
GT201500024A (es) Heterociclos de 5 miembros que contienen nitrógeno sustituidos por carboxamida o sulfonamida como moduladores para el receptor nuclear huérfano rory
UY35908A (es) Moduladores de tetrahidropiridopirazinas de gpr6
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CO7160047A2 (es) Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico (egfr)
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
CL2017000818A1 (es) Derivativos de benzotiofenil substituidos como agonistas gpr40 para el tratamiento de diabetes tipo ii
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CR20150425A (es) Compuestos azabencimidazol como inhibidores de las isozimas pde4, para el tratamiento del sistema nervioso central y otros desórdenes
IN2014MN02126A (es)
MX2013010670A (es) Derivados de benzo [b] [1, 4] oxazina como moduldores receptores de deteccion de calcio.
CL2017001292A1 (es) 4-oxo-3,4-dihidro-1,2,3-benzotraizinas como moduladores de gpr139
GT201000170A (es) Derivados de ciclopropilamina
CR11309A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonista de la histamnia-3
BR112017009629A2 (pt) triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2
CO6821958A2 (es) Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2
IN2014MN02127A (es)
UY33231A (es) Aminotiazolonas como moduladores de los receptores de estrógenos alfa
PA8827501A1 (es) Pirrolidin amidas sustituidas como moduladores del receptor histamina h3
UY33230A (es) Aminotiazolonas como moduladores del receptor alfa relacionados con estrógeno
CU20100045A7 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de la histamina-3